Ország: Egyesült Államok
Nyelv: angol
Forrás: NLM (National Library of Medicine)
GLYBURIDE (UNII: SX6K58TVWC) (GLYBURIDE - UNII:SX6K58TVWC)
Bryant Ranch Prepack
GLYBURIDE
GLYBURIDE 5 mg
ORAL
PRESCRIPTION DRUG
Glyburide tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Glyburide tablets are contraindicated in patients with: - Known hypersensitivity or allergy to the drug. - Diabetic ketoacidosis, with or without coma. This condition should be treated with insulin. - Type I diabetes mellitus. - Concomitant administration of bosentan.
Product: 63629-1393 NDC: 63629-1393-1 30 TABLET in a BOTTLE NDC: 63629-1393-2 120 TABLET in a BOTTLE NDC: 63629-1393-3 100 TABLET in a BOTTLE NDC: 63629-1393-4 60 TABLET in a BOTTLE NDC: 63629-1393-5 90 TABLET in a BOTTLE NDC: 63629-1393-6 180 TABLET in a BOTTLE
Abbreviated New Drug Application
GLYBURIDE- GLYBURIDE TABLET BRYANT RANCH PREPACK ---------- GLYBURIDE TABLETS USP 1.25, 2.5, AND 5 MG 8342 8343 8344 RX ONLY DESCRIPTION Glyburide tablets USP contain glyburide, USP, which is an oral blood-glucose-lowering drug of the sulfonylurea class. Glyburide, USP is a white, crystalline compound. The chemical name for glyburide, USP is 1-[[p-[2-(5-chloro-o-anisamido)ethyl]phenyl]-sulfonyl]-3-cyclohexylurea. It has the following structural formula: C H ClN O S M.W. 493.99 Each tablet, for oral administration, contains 1.25 mg, 2.5 mg or 5 mg of glyburide, USP. In addition, each tablet contains the following inactive ingredients: microcrystalline cellulose, pregelatinized corn starch, sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate. In addition, the 2.5 MG contains FD&C yellow No. 6 aluminum lake and the 5 MG contains D&C yellow No. 10 aluminum lake, and FD&C blue No. 1 aluminum lake. CLINICAL PHARMACOLOGY ACTIONS Glyburide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which glyburide lowers blood glucose during long-term administration has not been clearly established. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonylurea hypoglycemic drugs. The combination of glyburide and metformin may have a synergistic effect, since both agents act to improve glucose tolerance by different but complementary mechanisms. Some patients who are initially responsive to oral hypoglycemic drugs, including glyburide, may become unresponsive or poorly responsive over time. Alternatively, glyburide tablets may be effective in some patients who have become unresponsive to one or more other sulfonylurea drugs. In addition to its blood glucose lowering actions, Olvassa el a teljes dokumentumot